A citation-based method for searching scientific literature

Thomas Fremming Dejgaard, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Søren Urhammer, Ulrik Pedersen-Bjergaard, Tonny Jensen, Andreas Kryger Jensen, Jens Juul Holst, Lise Tarnow, Filip Krag Knop, Sten Madsbad, Henrik Ullits Andersen. Lancet Diabetes Endocrinol 2016
Times Cited: 71



Gayatri Sarkar, May Alattar, Rebecca J Brown, Michael J Quon, David M Harlan, Kristina I Rother. Diabetes Care 2014
Times Cited: 51




List of shared articles



Times cited

Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?
Harriet Warnes, Rebecca Helliwell, Sam Matthew Pearson, Ramzi A Ajjan. Diabetes Ther 2018
10

Pharmacological therapies to address obesity in type 1 diabetes.
Anna Casu, Anika Bilal, Richard E Pratley. Curr Opin Endocrinol Diabetes Obes 2020
0

Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial.
Nicklas Järvelä Johansen, Thomas Fremming Dejgaard, Asger Lund, Tina Vilsbøll, Henrik Ullits Andersen, Filip Krag Knop. BMJ Open 2018
2

Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects.
Jonatan I Bagger, Magnus F G Grøndahl, Asger Lund, Jens J Holst, Tina Vilsbøll, Filip K Knop. Diabetes 2021
0


Adjunctive therapy for glucose control in patients with type 1 diabetes.
Kira Harris, Cassie Boland, Lisa Meade, Dawn Battise. Diabetes Metab Syndr Obes 2018
9


Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial.
Nicklas J Johansen, Thomas F Dejgaard, Asger Lund, Camilla Schlüntz, Emil L Larsen, Henrik E Poulsen, Jens P Goetze, Holger J Møller, Tina Vilsbøll, Henrik U Andersen,[...]. Diabetes Obes Metab 2020
0


Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.
Nicklas J Johansen, Thomas F Dejgaard, Asger Lund, Camilla Schlüntz, Christian S Frandsen, Julie L Forman, Nicolai J Wewer Albrechtsen, Jens J Holst, Ulrik Pedersen-Bjergaard, Sten Madsbad,[...]. Lancet Diabetes Endocrinol 2020
10



Addition of glucagon-like peptide-1 receptor agonist therapy to insulin in C-peptide-positive patients with type 1 diabetes.
Nitesh D Kuhadiya, Ben Prohaska, Husam Ghanim, Paresh Dandona. Diabetes Obes Metab 2019
2


The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: A systematic review and meta-analysis.
Saniya Tandon, Salma Ayis, David Hopkins, Seeromanie Harding, Marietta Stadler. Diabetes Obes Metab 2021
1

Type 2 treatments for type 1 diabetes.
Zachary Bloomgarden, Guang Ning. J Diabetes 2016
1

GLP-1 Agonists in Type 1 Diabetes Mellitus.
Kristin M Janzen, Taylor D Steuber, Sarah A Nisly. Ann Pharmacother 2016
17

Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks.
Nitesh D Kuhadiya, Sandeep Dhindsa, Husam Ghanim, Aditya Mehta, Antoine Makdissi, Manav Batra, Sartaj Sandhu, Jeanne Hejna, Kelly Green, Natalie Bellini,[...]. Diabetes Care 2016
43